探花直播 of Cambridge - GSK

探花直播art of partnerships

skbf2 — Wed, 12 Feb 2025 17:44:23 +0000

Tammy Dougan on why it's so important that universities work with industry to get fundamental science out of the lab and into the real world.

Professor Duncan Richards appointed as Head of Department of Medicine

Anonymous — Fri, 06 Dec 2024 16:59:07 +0000

Professor Richards joins Cambridge from the 探花直播 of Oxford, where he has been since 2019. His particular research interest is the demonstration of clinical proof of concept of novel therapeutics through the application of experimental medicine techniques, especially human challenge studies.

As Climax Professor of Clinical Therapeutics, director of the Oxford Clinical Trial Research Unit (OCTRU), and the NIHR Oxford Clinical Research Facility, he led a broad portfolio focused on new medicines for multiple conditions. His focus has been the acceleration of promising new drug treatments through better decision-making in early phase clinical trials.

Professor Richards also brings with him a wealth of experience in a number of Pharmaceutical R&D clinical development roles. In 2003 he joined GSK and held a number of roles of increasing responsibility, latterly as Head of Clinical Pharmacology and Experimental Medicine, including directorship of GSK鈥檚 phase 1 and experimental medicine unit in Cambridge (CUC).

Commenting on his appointment, Professor Richards said: 鈥淎s a clinical pharmacologist, I have been fortunate to work across a broad range of therapeutic areas over the years. I am excited by the breadth and depth of expertise within the Department of Medicine and look forward to working with the first-class scientific team. My goal is to work with the Department team, the Clinical School, and hospitals to maximise the impact of the important work taking place in Cambridge.鈥�

Members of the department鈥檚 leadership team are looking forward to the continued development of the department under Professor Richards, building on its legacy of collaboration and groundbreaking translational research to drive our future success.

Professor Mark Wills, Interim Head of Department of Medicine, said: 鈥淒uncan brings to his new role a fantastic breadth of experience, which encompasses his clinical speciality in pharmacology, extensive experience of working within the pharmaceutical industry R&D at senior levels and most recently establishing academic clinical trials units and human challenge research facilities.

鈥淚 am very excited to welcome Duncan to the Department and looking forward to working with him, as he takes on the role of delivering of the Department of Medicine鈥檚 vision to increase the efficacy of translation of its world class fundamental research, and its impact upon clinical practice and patient wellbeing.鈥�

Menna Clatworthy, Professor of Translational Immunology and Director of the Cambridge Institute for Therapeutic Immunology and Infectious Disease (CITIID), said: "Duncan has a wealth of leadership experience in biomedicine, in both academia and pharma. That skillset will be invaluable in ensuring the Department of Medicine continues to deliver world-leading research to transform patient outcomes."

Charlotte Summers, Professor of Intensive Care Medicine and Director of the Victor Phillip Dahdaleh Heart & Lung Research Institute, said: 鈥淒uncan鈥檚 exemplary track record of translating fundamental scientific discoveries into therapies that benefit patients will help us further increase the impact of our research as we continue our mission to improve human health.鈥�

探花直播appointment underpins the recently announced five-year collaboration between GSK and the 探花直播 of Cambridge, the Cambridge-GSK Translational Immunology Collaboration (CG-TIC). 探花直播拢50 million investment will accelerate research and development in kidney and respiratory diseases to improve patient outcomes.

Professor Richards will assume the role in February 2025, replacing Interim Head of Department Dr Mark Wills who was appointed after the departure of Professor Ken Smith in January 2024.聽 Dr Wills will continue as Director of Research and Deputy Head of the Department of Medicine as well as leading his research group.聽

Professor Richards trained in medicine at Oxford 探花直播 and after junior doctor roles in London, he returned to Oxford as Clinical Lecturer in Clinical Pharmacology. His DM thesis research was on a translational model using platelet ion flux to interrogate angiotensin biology and he is author of the Oxford Handbook of Practical Drug Therapy and the 3rd edition of Drug Discovery and Development.

Professor Richards has been a core member of the UK COVID-19 Therapeutics Advisory Panel. He is a member of the Oxford Bioescalator Management Board, UK Prix Galien Prize Committee, and the therapeutic advisory committee of several national platform clinical trials.

Professor Duncan Richards has today been announced as the new Head of the Department of Medicine at the 探花直播 of Cambridge.

I am excited by the breadth and depth of expertise within the Department of Medicine and look forward to working with the first-class scientific team

Duncan Richards

探花直播text in this work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Images, including our videos, are Copyright 漏探花直播 of Cambridge and licensors/contributors as identified. All rights reserved. We make our image and video content available in a number of ways 鈥� on our main website under its Terms and conditions, and on a range of channels including social media that permit your use and sharing of our content under their respective Terms.

Yes

Cambridge and GSK announce new five-year collaboration aiming for improved outcomes for patients with hard-to-treat kidney and respiratory diseases

skbf2 — Sun, 20 Oct 2024 23:01:00 +0000

探花直播Cambridge-GSK Translational Immunology Collaboration (CG-TIC) combines 探花直播 and GSK expertise in the science of the immune system, AI and clinical development with access to patients and their data provided by Cambridge 探花直播 Hospitals.
GSK is investing more than 拢50 million in CG-TIC, further strengthening Cambridge鈥檚 position as Europe鈥檚 leading life sciences cluster.

GSK plc is making this investment to establish the Cambridge-GSK Translational Immunology Collaboration (CG-TIC), a five-year collaboration with the 探花直播 of Cambridge and Cambridge 探花直播 Hospitals. 探花直播collaboration is focused on understanding the onset of a disease, its progression, how patients respond to therapies and on developing biomarkers for rapid diagnosis. Ultimately, the goal is to trial more effective, personalised medicines.

探花直播collaboration will focus on kidney and respiratory diseases, both of which affect large numbers of people worldwide. Kidney disease is estimated to affect 850 million people (roughly 10% of the world鈥檚 population) (International Society of Nephrology) and chronic respiratory diseases around 545 million ( 探花直播Lancet).

Many types of kidney disease remain poorly understood and treatments, where they exist, tend to have limited efficacy. Chronic kidney disease is particularly unpleasant and debilitating for patients, often leading to end-stage disease. Treatments such as transplant and dialysis involve complex medical regimes and frequent hospital visits, making effective prevention and treatment the aim.

To make progress in treating these challenging disease areas, CG-TIC will apply an array of new techniques, including the use of cutting-edge single cell technologies to characterise how genes are expressed in individual cells. AI and machine learning have a critical role to play in transforming how data is combined and interrogated.

Using these techniques, the ambition is to be able to initiate new studies and early phase trials of new therapies for a number of hard-to-treat diseases which affect the kidneys. 探花直播same techniques will be applied to respiratory diseases and findings will be shared across the disease areas potentially to help identify and share better treatments across these different targets.

Peter Kyle, Secretary of State for Science, Innovation and Technology,聽welcomed the collaboration: " 探花直播UK's life sciences industry is thriving, driving innovation and improving lives. This collaboration between GSK and the 探花直播 of Cambridge demonstrates our country's leading research and development capabilities.

鈥淏y focusing on cutting-edge research and harnessing the power of AI, this has the potential to advance the treatment of immune-related diseases, which could benefit patients both here in the UK and internationally. It's a clear example of how collaboration between industry, academia, and healthcare can deliver tangible results and strengthen the UK's position in healthcare innovation."

Tony Wood, Chief Scientific Officer, GSK, added: 鈥淐ollaboration is at the heart of scientific progress and is fundamental to how we do R&D at GSK. We鈥檙e excited to build on our existing work with the 探花直播 of Cambridge to further this world-leading scientific and technological capability in the UK. By bringing together Cambridge鈥檚 expertise and our own internal capabilities, including understanding of the immune system and the use of AI to accelerate drug development, we have an opportunity to help patients struggling with complex disease.鈥�

探花直播aim of CG-TIC is to improve outcomes for patients and Cambridge provides a unique environment in which to involve them, with Cambridge 探花直播 Hospitals playing a pivotal role in the collaboration and Royal Papworth Hospital NHS Foundation Trust, the UK鈥檚 leading heart and lung hospital, a likely future partner.

Home to the hospitals and to much of the collaboration鈥檚 research activity, the Cambridge Biomedical Campus provides a unique environment where academia, industry and healthcare can come together and where human translational research is supported by the National Institute for Health and Care Research (NIHR) Cambridge Biomedical Research Centre.

Professor Deborah Prentice, Vice-Chancellor of the 探花直播 of Cambridge, said: 鈥� 探花直播探花直播 sits at the heart of Europe鈥檚 leading life sciences cluster, where excellent research and the NHS鈥檚 clinical resources combine with the talent generated by the many innovative bioscience companies that call Cambridge home. Through this very important collaboration with GSK, Cambridge will be able to drive economic growth for the UK while improving the health of people in this country and around the world.鈥�

Roland Sinker, CEO of Cambridge 探花直播 Hospitals NHS Foundation Trust, also welcomed the collaboration, saying: 鈥淲e are very excited to be part of this important partnership, which is another example of Cambridge experts working together to develop transformational new therapies, and use existing ones more precisely, to improve outcomes for patients with chronic and debilitating conditions.鈥�

探花直播Cambridge-GSK Translational Immunology Collaboration will be co-led by Nicolas Wisniacki, VP, Clinical Research Head, GSK (above left) and David Thomas, Professor of Renal Medicine, 探花直播 of Cambridge and principal investigator at the Cambridge Institute for Therapeutic Immunology and Infectious Diseases.

探花直播ambition of the partnership is to treat immune-related diseases more precisely with existing therapies and to rapidly develop new ones.

探花直播UK's life sciences industry is thriving, driving innovation and improving lives. This collaboration between GSK and the 探花直播 of Cambridge demonstrates our country's leading research and development capabilities.

Peter Kyle, Secretary of State for Science, Innovation and Technology

StillVision

David Thomas, Professor of Renal Medicine, 探花直播 of Cambridge and Dr Nicolas Wisniacki, VP, Clinical Research Head, GSK

Yes

Apollo Therapeutics secures $226.5 million to translate fundamental research into medicines

skbf2 — Wed, 06 Sep 2023 16:43:21 +0000

探花直播investment will be used to advance new treatments聽through clinical development and further fund Apollo鈥檚 drug discovery and development activities based on breakthroughs in basic medical research made at its partner research institutions. 探花直播financing will also be used to license or acquire additional clinical stage programmes that meet strict selection criteria.

Apollo has a scalable R&D platform for the discovery and development of new medicines. It selects programmes聽based on聽the quality of the science and their potential to transform the standard of care. This is enabled by an unprecedented level of access to world-class research institutions through partnership agreements.

Apollo Therapeutics was originally a six-way partnership devised by the technology transfer offices of three world-leading universities ( 探花直播 of Cambridge,聽Imperial College London聽and聽探花直播 College London) and embraced by pharmaceutical giants AstraZeneca, GlaxoSmithKline, and Johnson & Johnson Innovation. In June 2021, following a $145 million raise, Apollo became an independent biopharmaceutical company. 探花直播original partners all remain and have recently been joined by King鈥檚 College London and 探花直播Institute of Cancer Research.

This financing round was led by聽Patient Square Capita and聽significantly adds to the $195 million previously raised by聽Apollo Therapeutics.

鈥淲e are delighted to announce the close of our latest fundraise and wish to thank our existing investors for their continued support, as well as warmly welcoming all the new investors. Apollo has built a broad and diversified pipeline focused on major commercial markets and this latest fund-raising enables us to take our most advanced programs to key clinical value inflection points.鈥� Dr. Richard Mason, Chief Executive Officer of Apollo Therapeutics

鈥淚 have long believed in a business model for drug development characterized by extremely talented management, sufficient capital to pursue multiple programs and world-class science focused on unmet medical need. We are proud to support Apollo Therapeutics as it develops a number of promising medicines that we anticipate will eventually transform patient care.鈥� Jim Momtazee, Managing Partner of Patient Square Capital, and member of Apollo Therapeutic鈥檚 Board of Directors.

鈥淭his is a fantastic achievement, from a great team and great investors capitalising on a unique effective drug discovery and development model.聽 We are so proud to have been founders with great colleagues at Imperial College and UCL with our pharma partners AstraZeneca, GSK and Johnson and Johnson to deliver patient benefit from groundbreaking academic science.鈥澛� Dr Iain Thomas, Head of Life Sciences, Cambridge Enterprise

Adapted from a news release published by Cambridge Enterprise

Apollo Therapeutics, a biopharmaceutical company originally set up by three UK universities (Cambridge, Imperial College London聽and聽探花直播 College London) and three pharmaceutical companies (AstraZeneca, GSK聽and Johnson & Johnson Innovation), has secured $226.5 million venture capital financing.

Philippedelavie, Pixaby

test tubes

探花直播text in this work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Images, including our videos, are Copyright 漏探花直播 of Cambridge and licensors/contributors as identified.聽 All rights reserved. We make our image and video content available in a number of ways 鈥� as here, on our main website under its Terms and conditions, and on a range of channels including social media that permit your use and sharing of our content under their respective Terms.

Yes

Training a new breed of clinical triallist

skbf2 — Thu, 03 Feb 2022 11:48:27 +0000

Cambridge's Experimental Medicine Initiative, working with聽AstraZeneca and GSK, is training聽specialists who can work out at an earlier stage of clinical trials if a treatment is likely to succeed.

One man, three companies, tens of thousands of lives...

skbf2 — Fri, 22 Oct 2021 08:12:28 +0000

Professor Steve Jackson talks about drug discovery, serial entrepreneurship and the enterprising mindset.

鈥淏ehind every COVID-19 test sample is a person worried about their results鈥�

cg605 — Fri, 04 Sep 2020 11:38:56 +0000

Meet the volunteer scientists who turn swab samples into diagnoses 鈥� again and again and again.

Tackling COVID-19: Karl Wilson

Anonymous — Wed, 20 May 2020 23:27:00 +0000

On Friday 20 March, Karl Wilson, received a phone call which would turn his life upside-down for the next six weeks.

鈥淎fter a hectic week of closing down labs across the 探花直播, I was adjusting to my first day of working from home,鈥� remembers Wilson. 鈥淚鈥檇 managed a couple of hours work in my spare room (having just set up my new desk with the 鈥榟elp鈥� of my four year old daughter), when I received a call to say that the 探花直播 would be partnering with pharmaceutical giants AstraZeneca and GSK to set up a testing centre for Covid-19, in the newly built Anne McLaren Building.

鈥淚 knew it would be a huge undertaking but there was no question in my mind about it. It was just a case of 鈥榶es, let鈥檚 do this.鈥欌€�

An hour later Wilson found himself at the lab discussing floor plans, safety cabinets and sample-prepping-robots. 鈥淚t鈥檚 been a whirlwind ever since,鈥� he says.聽

A project of this scale would ordinarily take around six months to complete but incredibly the lab was ready to begin trialling tests in just three weeks. Wilson explained that this phenomenal feat was testament to the positive approach of everyone involved in the project. 鈥淭here鈥檚 never been any hesitation, never a question of 鈥榳hat鈥檚 in it for me?鈥� It鈥檚 always just been a case of 鈥榟ow can I help?鈥欌€�

It鈥檚 the small snippets of personal stories which demonstrate the dedication to the project of every individual involved. Wilson shares about a Programme Manager who left his family to move temporarily to Cambridge, to set up the IT infrastructure key to running the robotics. In another instance of generosity, two building firms, Mace and Mick George worked together to create a vital walkway to the test centre at short notice, and then waived fees of approximately 拢20,000. And from the very moment the project began, manufacturers have developed and supplied complex scientific equipment in a fraction of the time it would usually have taken them to do so.

Wilson says that the timely completion of the test centre was only possible through teamwork, collaboration, flexibility and the sheer number of hours put in by employees. It鈥檚 been estimated that 2292 hours have been worked overall to get us to this stage.

Wilson describes the feeling on site as being 鈥渧ery much a 鈥榗amp vibe.鈥欌€� He says, 鈥淵ou're thrusting a lot of people who don't know each other into a new situation, under very unusual circumstances. We were typically on site 13 hours a day 鈥� working together, talking together, eating together and taking time-out together. We all really bonded 鈥� you鈥檇 never have known we鈥檇 met for the first time just a few weeks before 鈥� it now feels like we鈥檝e been friends for years.鈥�

When days were tough it was the 鈥榳hy鈥� that kept the teams going. 鈥淲e were just thinking 鈥榯he quicker we get the centre open, the sooner we can help the country move forward, get out of lockdown, and hopefully return to some semblance of normality,鈥� says Wilson.聽

With the project nearing completion Wilson is finally able to catch his breath and begin to reflect on what has been both the greatest challenge and most rewarding venture of his career to date. He credits the success of the project to every individual involved who 鈥渏ust wanted to do a great job.鈥�

鈥淓veryone took real ownership of their roles and such pride in their work,鈥� he says. 鈥淚 think everyone is really pleased with what we鈥檝e accomplished.

鈥淲e鈥檙e excited to see the lab in action and, in a sense, see the fruits of our labour. And one day, hopefully in the not too distant future, we鈥檙e all looking forward to going out together, to raise a toast to the success of a job well done.鈥�

聽

This article is part of a聽series聽in which we speak to some of the many Cambridge researchers tackling COVID-19. For other articles聽about our latest COVID-19-related research, click聽here.

聽

Operations Director Karl Wilson has helped lead a herculean effort to transform a standard laboratory into a bespoke testing centre, to aid the national response against COVID-19. For him, there was never any question about whether we should - or could - do this.

Everyone took real ownership of their roles and such pride in their work. I think everyone is really pleased with what we鈥檝e accomplished

Karl Wilson

探花直播text in this work is licensed under a Creative Commons Attribution 4.0 International License. Images, including our videos, are Copyright 漏探花直播 of Cambridge and licensors/contributors as identified.聽 All rights reserved. We make our image and video content available in a number of ways 鈥� as here, on our main website under its Terms and conditions, and on a range of channels including social media that permit your use and sharing of our content under their respective Terms.

Yes